{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-036294","form_type":"8-K","ticker":"FEMY","cik":"0001339005","company_name":"FEMASYS INC","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.714180+00:00","generated_at":"2026-05-31T10:44:52.337077+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Femasys Q2 2024 revenue down 31% YoY to $221K; net loss widens to $4.7M","bullets":["Q2 2024 sales of $221,484, down 31% from $320,514 in Q2 2023.","Net loss of $4.68M ($0.21 per share) compared to $2.89M ($0.22 per share) a year ago.","Cash and cash equivalents $13.5M; expects to fund operations into July 2025.","Received CE Mark for four women's health products; completed U.S. commercial team build-out."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-036294","json":"https://secwatch.observer/filing/0001140361-24-036294.json","markdown":"https://secwatch.observer/filing/0001140361-24-036294.md","text":"https://secwatch.observer/filing/0001140361-24-036294.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339005/000114036124036294/0001140361-24-036294-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339005/000114036124036294/ef20033802_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:44:52.337077+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}